Biotechnology

FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, July 24, 2024  /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold ki...

2024-07-24 08:10 2643

Telix Successfully Prices A$650 Million Convertible Bonds

MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...

2024-07-24 07:51 2726

Telix Announces A$600 Million Convertible Bonds Offering

MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...

2024-07-23 16:35 2495

SND Introduces Revolutionary Moderated Drinking Treatment Program

TOKYO, July 23, 2024 /PRNewswire/ -- SND Incorporated (Headquarters: Chiyoda-ku, Tokyo; CEO: Takayuki Hiiragi) is proud to announce the launch of its groundbreaking Moderated Drinking Treatment Program for alcohol dependency. This innovative approach offers a compassionate alternative to tradition...

2024-07-23 16:29 2624

QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs

SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX , a computational drug discovery company, today announced a collaboration with Prelude Therapeutics , a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets....

2024-07-23 08:00 2537

DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease

* Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials * Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRNewswire/ --  DiscGenics, Inc., a privately held, l...

2024-07-23 08:00 2287

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...

2024-07-22 19:48 3539

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...

2024-07-22 19:00 3169

Join Hands for a Brighter Future!2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition Overseas Event (Hong Kong SAR Division) Concluded Successfully

HONG KONG, July 22, 2024 /PRNewswire/ -- On July 17, 2024, the Hong Kong SAR division of the 2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition concluded successfully. Top scientists, business leaders, government officials, and elite entrepreneurs from around the world gathe...

2024-07-22 16:41 2571

Duke-NUS launches LIVE Ventures, a S$20 million incubator to accelerate research commercialisation

* New incubator aims to tap industry experts to bridge the knowledge and funding gap to enhance bench-to-bedside success * LIVE Ventures provides up to $500,000 for high-potential academic research projects SINGAPORE, July 22, 2024 /PRNewswire/ -- Duke-NUS Medical School today launched LIVE V...

2024-07-22 10:00 2735

Agilent Introduces New ProteoAnalyzer at Singapore Cell and Gene Therapy Pan Asia Summit

SINGAPORE, July 22, 2024 /PRNewswire/ -- Agilent Technologies Inc.  (NYSE: A) today an...

2024-07-22 09:12 3467

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...

2024-07-22 09:00 2608

Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-07-22 08:00 4045

DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment

* Confirmation of effects compared to global late-stage clinical trials * Accelerating the development of obesity treatment through early licensing out, global joint clinical trials, research funding investment, etc. SEOUL, South Korea, July 18, 2024 /PRNewswire/ -- DX&VX, which is gaining att...

2024-07-18 21:00 3149

BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards

Recognized for excellence in writing, news, mental health, financial/investment and economics categories LONDON, July 18, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc  (NYSE:CLVT), a leading global provider of transformative intelligence, has been honored with nine2024 APEX Awards fo...

2024-07-18 15:00 2349

Getinge Interim Report April-June 2024: Higher sales, stronger margins and product launches with significant added value for customers

GOTHENBURG, Sweden, July 18, 2024 /PRNewswire/ -- "Net sales increased by 15.7% in the second quarter, of which the organic increase was 8.9%," says Mattias Perjos, President & CEO at Getinge. "The operating margin improved compared with last year due to strong sales and a positive product mix, w...

2024-07-18 14:33 2311

Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore

Dedicated mobile app to encourage proactive management of physical health, mental well-being and chronic disease SINGAPORE, July 18, 2024 /PRNewswire/ -- With the advancements in medical sciences, there is now very little difference between the life expectancy of people with HIV (PWH) and the ge...

2024-07-18 13:45 2431

PairX Bio Clinches Coveted Amgen Golden Ticket Award, as NSG BioLabs Deepens Efforts with Partners CapitaLand and Amgen to Boost Singapore's Biotech Ecosystem with Fourth Site and Extended Awards Programme

* The Amgen Golden Ticket Award, now in its third year, showcases Amgen's and NSG BioLabs' efforts to support high-growth startups in a nurturing ecosystem, with a doubling of applicants compared to last year * Amgen and NSG BioLabs extended the Golden Ticket partnership for another three y...

2024-07-18 10:00 4136

China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products

SHENZHEN, China, July 18, 2024 /PRNewswire/ -- The 90th China International Medical Equipment Fair (CMEF) is set to take place inShenzhen from October 12th to 15th, 2024. With an expected attendance of over 200,000 visitors from more than 150 countries, the exhibition is poised to be a global sho...

2024-07-18 09:50 4140

Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration

SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced thatChina's National Medical Products ...

2024-07-18 08:00 2844
1 ... 44454647484950 ... 186

Week's Top Stories